Expanding analyst interest in ORYZON
New U.S. investment bank joins, bringing total coverage to ten analysts.
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that Maxim LLC, a U.S.-based investment bank, has initiated research coverage of the company, effective July 18, 2025.
This milestone reflects Oryzon’s ongoing commitment to transparency and proactive communication with the investment community. Over the years, the company has consistently worked to communicate the clinical value of its programs, the unmet medical needs they aim to address, and their commercial potential, engaging with a broad network of biotech analysts. Oryzon firmly believes that independent, high-quality research is essential for helping biotech investors make informed portfolio decisions.
With the addition of Maxim LLC, Oryzon is now covered by ten financial analysts, further enhancing the company's visibility in global capital markets. The current analyst coverage includes:
- United States: ROTH Capital Partners, Maxim LLC
- United Kingdom: Jefferies, Rx Securities, Edison Group
- Continental Europe: Van Lanschot Kempen, Invest Securities, JBCapital, Estrategias de Inversión, Luis Navia
This level of coverage places Oryzon among the most broadly followed European biotech companies, underscoring the company’s leadership and growing relevance in the sector.
Please note: Any opinions, estimates, or forecasts regarding Oryzon Genomics, S.A.’s performance made by these analysts are theirs alone and do not represent the views or guidance of Oryzon Genomics, S.A. or its management. Reference to or distribution of such coverage does not imply endorsement or concurrence by the company.